Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

PNAS 106 (20): 8221-8226

Copyright © 2009 by the National Academy of Sciences.


BIOLOGICAL SCIENCES / CELL BIOLOGY

The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42

Karthikeyan Mythreyea Gerard C. Blobea,b,1

Departments of aMedicine and bPharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27708

Edited by Robert J. Lefkowitz, Duke University Medical Center, Durham, NC, and approved March 19, 2009

Received for publication December 17, 2008.

Abstract: Loss of expression of the TGF-β superfamily coreceptor, the type III TGF-β receptor (TβRIII or betaglycan), occurs in a broad spectrum of human cancers including breast, lung, ovarian, pancreatic, prostate, and renal cell cancer. TβRIII suppresses cancer progression in vivo, at least in part, by reducing cancer cell motility. However, the mechanism by which TβRIII regulates migration is unknown. Here, we demonstrate an unexpected TGF-β signaling independent role for TβRIII in activating Cdc42, altering the actin cytoskeleton and reducing directional persistence to inhibit random migration of both cancer and normal epithelial cells. Functionally, TβRIII through its interaction with the scaffolding protein β-arrestin2, activates Cdc42 and inhibits migration. These studies identify a TGF-β independent homeostatic function for TβRIII in regulating cell migration.


Author contributions: K.M. and G.C.B. designed research; K.M. performed research; K.M. and G.C.B. analyzed data; and K.M. and G.C.B. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This article contains supporting information online at www.pnas.org/cgi/content/full/0812879106/DCSupplemental.

1To whom correspondence should be addressed. E-mail: blobe001{at}mc.duke.edu


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A Systems Biology Approach Identifies Effective Tumor-Stroma Common Targets for Oral Squamous Cell Carcinoma.
W. Meng, Y. Wu, X. He, C. Liu, Q. Gao, L. Ge, L. Wu, Y. Liu, Y. Guo, X. Li, et al. (2014)
Cancer Res. 74, 2306-2315
   Abstract »    Full Text »    PDF »
Characterization of a Cdc42 Protein Inhibitor and Its Use as a Molecular Probe.
L. Hong, S. R. Kenney, G. K. Phillips, D. Simpson, C. E. Schroeder, J. Noth, E. Romero, S. Swanson, A. Waller, J. J. Strouse, et al. (2013)
J. Biol. Chem. 288, 8531-8543
   Abstract »    Full Text »    PDF »
{beta}-Arrestin-Dependent Actin Reorganization: Bringing the Right Players Together at the Leading Edge.
J. Min and K. DeFea (2011)
Mol. Pharmacol. 80, 760-768
   Abstract »    Full Text »    PDF »
Mechanical Stiffness Grades Metastatic Potential in Patient Tumor Cells and in Cancer Cell Lines.
V. Swaminathan, K. Mythreye, E. T. O'Brien, A. Berchuck, G. C. Blobe, and R. Superfine (2011)
Cancer Res. 71, 5075-5080
   Abstract »    Full Text »    PDF »
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling.
L. M. Luttrell, D. Gesty-Palmer, and D. R. Sibley (2010)
Pharmacol. Rev. 62, 305-330
   Abstract »    Full Text »    PDF »
Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-{beta} signaling at the bipotent erythro-megakaryocytic progenitor stage.
V. Randrianarison-Huetz, B. Laurent, V. Bardet, G. C. Blobe, F. Huetz, and D. Dumenil (2010)
Blood 115, 2784-2795
   Abstract »    Full Text »    PDF »
The type III TGF-{beta} receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-{beta} signaling.
J. D. Lee, N. Hempel, N. Y. Lee, and G. C. Blobe (2010)
Carcinogenesis 31, 175-183
   Abstract »    Full Text »    PDF »
The Transforming Growth Factor-{beta} Type III Receptor Mediates Distinct Subcellular Trafficking and Downstream Signaling of Activin-like Kinase (ALK)3 and ALK6 Receptors.
N. Y. Lee, K. C. Kirkbride, R. D. Sheu, and G. C. Blobe (2009)
Mol. Biol. Cell 20, 4362-4370
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882